StockNews.AI
ESPR
StockNews.AI
182 days

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

1. Esperion will report Q3 2024 financial results on March 4, 2025. 2. Management will discuss results via a webcast at 8:00 a.m. ET. 3. Esperion focuses on non-statin medicines for cardiovascular disease management. 4. Their drugs are supported by a major 14,000 patient clinical trial. 5. The company is advancing its drug pipeline with ACLYi inhibitors.

Earnings
+3.23%Current Return
VS
+0.52%S&P 500
$1.8602/18 08:07 AM EDTEvent Start
$1.9202/19 02:50 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings reports can attract investor attention, often boosting stock prices. Past earnings rallies support this tendency for biopharmaceutical companies post-announcement.

How important is it?

The article pertains directly to upcoming financial results that could impact ESPR. Financial performance is crucial for future growth and market confidence.

Why Short Term?

Earnings announcements typically influence stock price in the immediate term. Similar patterns have been observed in previous quarterly results for biopharmaceutical stocks.

Related Companies

ESPR
February 18, 2025 08:00 ET  | Source: Esperion Therapeutics, Inc. ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X. Esperion Contact Information: Investors: Alina Veneziainvestorrelations@esperion.com (734) 887-3903 Media: Tiffany Aldrich corporateteam@esperion.com (616) 443-8438

Related News